As we continue to welcome our summer interns from Project Onramp, a program of Life Science Cares Boston, we are grateful to our many partners who have generously provided their support and resources to make this initiative a success. We appreciate the invaluable contributions of these partners in empowering the next generation of scientists and innovators. • ChemDraw is a software product from Revvity Signals that offers powerful tools for drawing chemical structures and reactions, widely used in chemical research and education. • SciFinder is a research discovery application that provides access to a comprehensive and authoritative source of references, substances, and reactions in chemistry and related fields, developed by CAS. • LiveDesign is a collaborative drug design platform from Schrödinger that integrates data and computational models to enhance the drug discovery process. • Conga provides digital transformation solutions, including document generation, contract lifecycle management, and process automation, to streamline business operations and improve efficiency.
Nimbus Therapeutics
Biotechnology Research
Cambridge, Massachusetts 14,640 followers
Applying deep computational chemistry expertise to create novel small molecule therapeutics.
About us
At Nimbus, we design breakthrough medicines. Utilizing our powerful structure-based drug discovery engine, we create potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. With a decade-plus track record of success, we’ve built a world-class team in both computationally driven drug discovery and early clinical development while continuing to move the needle for patients.
- Website
-
http://www.nimbustx.com/
External link for Nimbus Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Specialties
- computational chemistry, biochemistry, small molecule therapeutics, oncology, immunology, metabolism, and drug development
Locations
-
Primary
130 Prospect St
Ste 301
Cambridge, Massachusetts 02139, US
Employees at Nimbus Therapeutics
Updates
-
For our latest #Nimbi Giving Back Day, our team partnered with two incredible LGBTQ+ organizations in honor of #PrideMonth. Together we created self-care, hygiene, and welcome kits to support Friendship Works, an organization that helps to decrease LGBTQ+ elder isolation, and Waltham House, part of The Home for Little Wanderers that assists LGBTQ+ teens with a safe place to live.
-
-
On the “Healthscape” podcast from Northwestern University - Kellogg School of Management, our Chief Business Officer Abbas Kazimi talks about what drives authentic communication. “I’ve had a family history of cancer. This is why I want to challenge myself. And that authenticity opens the door for my colleagues to share their own personal experiences with illnesses… why they work in our industry… why they are so passionate.” Find the episode here: https://lnkd.in/dru-7-_9
-
-
We took our summer interns from Project Onramp out to the ballgame! Many thanks to Life Science Cares Boston for creating wonderful opportunities for these talented young individuals who represent the future of #lifesciences.
-
-
Our Director of Computational Chemistry, Leela Sriram Dodda, Ph.D., is in Seattle this week for the 38th National Medicinal Chemistry Symposium organized by the ACS Division of Medicinal Chemistry. It’s a great opportunity to highlight how we are using physics-based #MachineLearning methods to accelerate the design of novel chemical matters with computation. #NMCS2024 #MedicinalChemistry
Join us in Seattle, WA, US on June 23-26, 2024, for the 38th National Medicinal Chemistry Symposium organized by the ACS Division of Medicinal Chemistry. Follow our cutting-edge program chaired by Rheem Totah and Patrick Burke. Early-bird registration deadline is February 14, while poster abstracts can be submitted until March 14 ⌛ ✅ Visit www.nmcsmedi.org for details. Don't miss out! #NMCS2024 #MedicinalChemistry
-
-
#ICYMI our Chief Executive Officer Jeb Keiper talked with Endpoints News about HPK1, a differentiated next-generation #immunotherapy target for advanced solid tumors. Read the article here: https://lnkd.in/e-KAkZ4z
-
In recognition of #Juneteenth take a moment to read this powerful paper developed by more than 50 Black scientists who provide context around the barriers to equality in STEMM including a lack of recognition and exclusion from training. The authors offer steps to improve mentoring and institutional support to reduce these barriers. Learn more via Cell Press here: https://lnkd.in/e-YsKcCj
-
-
Today our Chief Executive Officer Jeb Keiper is moderating a panel on innovation in #DrugDiscovery during the Longwood Healthcare Leaders Spring MIT meeting. He’s joined by a group of top #biopharma executives who will share insights on what makes a discovery disruptive and how to measure and incentivize innovation. https://lnkd.in/exxKDits #LongwoodHealthcareLeaders
-
-
The #Nimbi team was proud to participate in Bio-Ball 2024 to support Special Olympics athletes and encourage inclusion and community! Thanks to our team’s incredible fundraising effort, the Nimbus/Haverhill Team won the opportunity to compete on the parquet floor at TD Garden in November! Looking forward to the rematch! #bioball #ChooseToInclude
-
-
At the American Society of Clinical Oncology (ASCO) Annual Meeting, our Chief Executive Officer Jeb Keiper met with Brad Loncar, Founder of BiotechTV, to talk about our investigational HPK1 inhibitor in the treatment of advanced solid tumors. See the video below. #ASCO24
𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟒: Nimbus Therapeutics CEO Jeb Keiper on the company's HPK1 data at #ASCO24. He describes the HKP1 pathway and why he believes his company's expertise in precision engineering and machine learning has helped it discover and develop this asset. Full video: https://lnkd.in/g5XH2fAg BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent